ANTIBODIES

Contributor Information
- Name Karen Pulford
- Institute University of Oxford
Tool Details
- Tool name: Anti-LILR [GHI/75]
- Clone: GHI/75
- Tool type: Antibodies
- Tool sub-type: Primary Antibody
- Class: Monoclonal
- Conjugate: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IHC ; IF ; IP ; WB
- Description: LILR is a 120kD membrane glycoprotein expressed strongly on plasma cells, moderately on circulating B cells and weakly on monocytes. It is not expressed on neutrophils, T cells, NK cells or any non-hematopoietic cells.
- Immunogen: Hairy cell leukaemia cells
- Isotype: IgG2b
- Research area: Immunology
- Myeloma used: P3/NS1/1-Ag4.1
- For Research Use Only
Target Details
- Target: Leukocyte Immunogolobulin-like Receptor 1 (LILR, CD85)
- Target background: LILR is a 120kD membrane glycoprotein expressed strongly on plasma cells, moderately on circulating B cells and weakly on monocytes. It is not expressed on neutrophils, T cells, NK cells or any non-hematopoietic cells.
Application Details
- Application: FACS ; IHC ; IF ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15ðC to -25ðC
- Shipping conditions: Shipping at 4ðC
Related Tools
References
- • Morel et al. 2008. J Immunol. 181(4):2368-81. PMID: 18684926.
- • HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j.
- • Kirwan et al. 2005. J Immunol. 175(8):5006-15. PMID: 16210603.
- • Killer cell Ig-like receptor-dependent signaling by Ig-like transcript 2 (ILT2/CD85j/LILRB1/LIR-1).
- • Banham et al. 1999. J Leukoc Biol. 65(6):841-5. PMID: 10380908.
- • Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily.
- • Pulford et al. 1991. Clin Exp Immunol. 85(3):429-35. PMID: 1893623.
- • A 72-kD B cell-associated surface glycoprotein expressed at high levels in hairy cell leukaemia and plasma cell neoplasms.